Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...
TAG and 82 other organizations and 106 individuals representing TB-affected communities and civil society sent an open letter to Johnson & Johnson calling on the company...
As we close another year of unprecedented challenges and achievements, I'm honored to share with you Treatment Action Group's (TAG) 2022 Annual Report.
On 15 June, 2023, TB Europe Coalition (TBEC) organized a webinar featuring a presentation by Treatment Action Group’s TB Project Officer, David Branigan, on the practical actions advocates can take to promote the adoption and scale up of shorter, safer 1/4/6 regimens for TB prevention and the treatment of drug-sensitive and drug-resistant TB as well as supportive diagnostics.
Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB) is a five-year cooperative agreement made possible by the United States Agency for International Development (USAID), with the assistance of the American people, that aims to transform tuberculosis (TB) prevention and care.
TAG recently submitted this input for the Office of the High Commissioner on Human Rights (ONHCR) Independent Expert on Foreign Debt and Human Rights thematic report for the UN General Assembly 78 later this year.
Save the date for Monday, October 19! TAG’s 2023 Research in Action Awards will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world.